{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:10:00Z","timestamp":1792271400621,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16LW0239K"],"award-info":[{"award-number":["16LW0239K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["MSTARS-2"],"award-info":[{"award-number":["MSTARS-2"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.modpat.2025.100753","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:45:13Z","timestamp":1741783513000},"page":"100753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management"],"prefix":"10.1016","volume":"38","author":[{"given":"Gabriel","family":"Dernbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-4598","authenticated-orcid":false,"given":"Marie-Lisa","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea P.","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Jurczok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jurmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Bastian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.modpat.2025.100753_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41416-023-02543-0","article-title":"Systemic anticancer therapy for urothelial carcinoma: UK oncologists\u2019 perspective","volume":"130","author":"Jones","year":"2024","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1016\/j.modpat.2025.100753_bib4","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100753_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.modpat.2025.100753_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-drug conjugates for cancer therapy: chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2025.100753_bib10","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/curroncol31040172","article-title":"Antibody-drug conjugates in the treatment of genitourinary cancers: an updated review of data","volume":"31","author":"Nathan","year":"2024","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2025.100753_bib11","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/cancers15061744","article-title":"Overview of trop-2 in cancer: from pre-clinical studies to future directions in clinical settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.modpat.2025.100753_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.modpat.2025.100753_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.modpat.2025.100753_bib14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yao.2023.01.010","article-title":"The future of antibody\u2013drug conjugates in urothelial cancer: new indications and novel targets","volume":"3","author":"Goodson","year":"2023","journal-title":"Adv Oncol"},{"issue":"20","key":"10.1016\/j.modpat.2025.100753_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2025.100753_bib17","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.modpat.2025.100753_bib18","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2025.100753_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.modpat.2025.100753_bib20","series-title":"Urothelial Carcinoma: Methods and Protocols","first-page":"53","article-title":"Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel","author":"Sj\u00f6dahl","year":"2018"},{"issue":"5","key":"10.1016\/j.modpat.2025.100753_bib21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2023.03.012","article-title":"Intratumoral heterogeneity of molecular subtypes in muscle-invasive bladder cancer-an extensive multiregional immunohistochemical analysis","volume":"9","author":"Schallenberg","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"17","key":"10.1016\/j.modpat.2025.100753_bib22","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100753_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41587-024-02168-5","article-title":"Cancer-targeting antibody\u2013drug conjugates drive dealmaking frenzy","volume":"42","author":"Senior","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"20","key":"10.1016\/j.modpat.2025.100753_bib25","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100753_bib26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.modpat.2025.100753_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104571","article-title":"Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment","volume":"91","author":"Li","year":"2023","journal-title":"eBioMedicine"},{"issue":"4","key":"10.1016\/j.modpat.2025.100753_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.modpat.2025.100753_bib29","doi-asserted-by":"crossref","first-page":"38372","DOI":"10.18632\/oncotarget.5368","article-title":"Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens","volume":"6","author":"Ahn","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.modpat.2025.100753_bib30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.modpat.2025.100753_bib33","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","article-title":"Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort","volume":"39","author":"Weyerer","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.modpat.2025.100753_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.modpat.2025.100753_bib35","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2025.100753_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2020.10.006","article-title":"Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Grigg","year":"2021","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2025.100753_bib37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.modpat.2025.100753_bib38","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2025.100753_bib39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/carcin\/bgy095","article-title":"Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition","volume":"39","author":"Rem\u0161\u00edk","year":"2018","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib40","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3892\/etm.2017.4788","article-title":"Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells","volume":"14","author":"Wu","year":"2017","journal-title":"Exp Ther Med"},{"issue":"10","key":"10.1016\/j.modpat.2025.100753_bib41","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hed.23138","article-title":"Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma","volume":"35","author":"Wu","year":"2013","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.modpat.2025.100753_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.96","article-title":"Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis","volume":"5","author":"Wang","year":"2014","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/ijms23010087","article-title":"Impact of spatially heterogeneous trop-2 expression on prognosis in oral squamous cell carcinoma","volume":"23","author":"Erber","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.modpat.2025.100753_bib44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of nectin-4 and trop-2 in variant histology: a rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"10.1016\/j.modpat.2025.100753_bib45","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2025.100753_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395225000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:58:48Z","timestamp":1777579128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395225000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0893395225000493"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100753","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2025.100753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100753"}}